Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3733687 | 0.92 | NAMPT (0.49) | NAMPTICAM1DDB1CRBN | |
| SCHEMBL3741303 | 0.92 | NAMPT (0.47) | NAMPTICAM1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3738611 | 0.90 | NAMPT (0.50) | NAMPTMEN1KMT2ADDB1CRBN | |
| SCHEMBL3731650 | 0.89 | NAMPT (0.52) | NAMPTICAM1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3734785 | 0.88 | NAMPT (0.47) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3734293 | 0.86 | NAMPT (0.45) | NAMPTICAM1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3733465 | 0.86 | NAMPT (0.47) | NAMPTICAM1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3736394 | 0.85 | NAMPT (0.45) | NAMPTMEN1KMT2ADDB1CRBN | |
| SCHEMBL4760966 | 0.85 | NAMPT (0.46) | NAMPTMEN1KMT2ADDB1CRBN | |
| SCHEMBL3738813 | 0.84 | NAMPT (0.46) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | claimed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | claimed |
| EP-1959947-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | disclosed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1959947-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197505-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885ICAM1 2076/4885MEN1 4493/4885 |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885ICAM1 2340/4885MEN1 4319/4885 |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885ICAM1 2076/4885MEN1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.